C Grodner1, A Beauchet2, A-C Fougerousse3, N Quiles-Tsimaratos4, J-L Perrot5, H Barthelemy6, J Parier7, F Maccari7, N Beneton8, D Bouilly-Auvray9, M Ruer-Mulard10, C Boulard11, C Jacobzone12, D Thomas-Beaulieu13, D Pourchot13, L Méry-Bossard13, G Chaby14, C Girard15, A-B Duval-Modeste16, A Vermersch-Langlin17, J Delaunay18, S Marc19, M Kemula20, M Steff21, P Bilan21, A-L Liégeon22, H Aubert23, B Solyga24, N Kluger25,26, E Mahé1. 1. Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France. 2. Public Health Department, Hôpital Ambroise Paré, Boulogne-Billancourt, France. 3. Dermatology Department, Hôpital d'Instruction des Armées Bégin, Saint Mandé, France. 4. Dermatology Department, Hôpital Saint-Joseph, Marseille, France. 5. Dermatology Department, CHU Saint-Etienne, Saint-Etienne, France. 6. Dermatology Department, Centre Hospitalier d'Auxerre, Auxerre, France. 7. Private Office, La Varenne St Hilaire, France. 8. Dermatology Department, Centre Hospitalier du Mans, Le Mans, France. 9. Dermatology Department, Centre Hospitalier Universitaire de Dijon, Dijon, France. 10. Private Office, Martigues, France. 11. Dermatology Department, Hôpital Jacques Monod, Le Havre Cedex, France. 12. Dermatology Department, Centre Hospitalier de Lorient, Lorient, France. 13. Dermatology Department, Centre Hospitalier Intercommunal de Poissy/Saint-Germain-en-Laye, Saint-Germain-en-Laye, France. 14. Dermatology Department, Hôpital Sud, Amiens, France. 15. Dermatology Department, Centre Hospitalier Universitaire de Montpellier, Montpellier, France. 16. Dermatology Department, Centre Hospitalier Universitaire Charles-Nicolle, Rouen, France. 17. Dermatology Department, Hôpital Jean Bernard, Valenciennes, France. 18. Dermatology Department, Angers, France. 19. Dermatology Department, Hôpital François Quesnay, Mantes La Jolie, France. 20. Private Office, Paris, France. 21. Dermatology Department, Hôpital Intercommunal Robert-Ballanger, Aulnay-sous-Bois, France. 22. Dermatology Department, Hôpital de Valence, Valence, France. 23. Dermatology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France. 24. Private Office, Fontenay-sous-Bois, France. 25. Dermatology Department, Allergology, and Venereology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. 26. Dermatology Department, Tattoo Consultation, Centre Hospitalier Universitaire Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France.
Abstract
BACKGROUND: Tattooing is a widespread phenomenon, with an estimated prevalence of 10-30% in Western populations. For psoriasis patients, current recommendations are to avoid having a tattoo if the disease is active and they are receiving immunosuppressive treatments. Although scientific data supporting these recommendations are lacking, dermatologists are often reluctant to advocate tattooing in psoriasis patients. OBJECTIVE: We aimed to evaluate the frequency of tattoo complications in patients with psoriasis and determine whether the occurrence of complications was associated with psoriasis status and treatments received at the time of tattooing. METHODS: We performed a multicentre cross-sectional study. Adults with psoriasis were consecutively included and classified as tattooed or non-tattooed. Prevalence of complications associated with tattoos was then evaluated according to psoriasis onset and treatments. The study was divided into three parts, in which data were collected through a series of questionnaires filled in by the dermatologist. Complications included pruritus, oedema, allergic reaction/eczema, infection/superinfection, granuloma, lichenification, photosensitivity, Koebner phenomenon and psoriasis flare after tattooing. Diagnosis of complications was made retrospectively. RESULTS: We included 2053 psoriatic patients, 20.2% had 894 tattoos. Amongst non-tattooed patients, 15.4% had wished to be tattooed, with psoriasis being stated as a reason for not having a tattoo by 44.0% and 5.7% indicating that they planned to have a tattoo in the future. Local complications, such as oedema, pruritus, allergy and Koebner phenomenon, were reported in tattoos in 6.6%, most frequently in patients with psoriasis requiring treatment at the time of tattooing (P < 0.0001). No severe complications were reported. CONCLUSIONS: The rate of tattoo complications in psoriasis patients was low. Although the risk of complications was highest amongst patients with psoriasis requiring treatment at the time of tattooing, all the complications observed were benign. These results can be helpful for practitioners to give objective information to patients.
BACKGROUND: Tattooing is a widespread phenomenon, with an estimated prevalence of 10-30% in Western populations. For psoriasispatients, current recommendations are to avoid having a tattoo if the disease is active and they are receiving immunosuppressive treatments. Although scientific data supporting these recommendations are lacking, dermatologists are often reluctant to advocate tattooing in psoriasispatients. OBJECTIVE: We aimed to evaluate the frequency of tattoo complications in patients with psoriasis and determine whether the occurrence of complications was associated with psoriasis status and treatments received at the time of tattooing. METHODS: We performed a multicentre cross-sectional study. Adults with psoriasis were consecutively included and classified as tattooed or non-tattooed. Prevalence of complications associated with tattoos was then evaluated according to psoriasis onset and treatments. The study was divided into three parts, in which data were collected through a series of questionnaires filled in by the dermatologist. Complications included pruritus, oedema, allergic reaction/eczema, infection/superinfection, granuloma, lichenification, photosensitivity, Koebner phenomenon and psoriasis flare after tattooing. Diagnosis of complications was made retrospectively. RESULTS: We included 2053 psoriaticpatients, 20.2% had 894 tattoos. Amongst non-tattooed patients, 15.4% had wished to be tattooed, with psoriasis being stated as a reason for not having a tattoo by 44.0% and 5.7% indicating that they planned to have a tattoo in the future. Local complications, such as oedema, pruritus, allergy and Koebner phenomenon, were reported in tattoos in 6.6%, most frequently in patients with psoriasis requiring treatment at the time of tattooing (P < 0.0001). No severe complications were reported. CONCLUSIONS: The rate of tattoo complications in psoriasispatients was low. Although the risk of complications was highest amongst patients with psoriasis requiring treatment at the time of tattooing, all the complications observed were benign. These results can be helpful for practitioners to give objective information to patients.
Authors: Georg Schett; Proton Rahman; Christopher Ritchlin; Iain B McInnes; Dirk Elewaut; Jose U Scher Journal: Nat Rev Rheumatol Date: 2022-05-05 Impact factor: 20.543